How should I manage persistent tremor and anxiety in a 57‑year‑old woman with bipolar I disorder who was stable on aripiprazole (Abilify) but developed these symptoms, and whose tremor continued after switching to quetiapine?

Management of Persistent Tremor and Anxiety in Bipolar I Disorder After Antipsychotic Switch

The shakiness is most likely akathisia from aripiprazole, which persisted after switching to quetiapine because the underlying mechanism was never addressed; immediately discontinue the current antipsychotic, add propranolol 20–40 mg twice daily for tremor control, and initiate a mood stabilizer (lithium or valproate) as definitive treatment for bipolar I disorder. 1, 2, 3

Understanding the Clinical Picture

Aripiprazole-Induced Akathisia and Anxiety

• Aripiprazole causes akathisia in approximately 25% of patients with bipolar disorder, manifesting as inner restlessness, anxiety, and tremor that patients often describe as "shakiness." 1
• The FDA label explicitly documents that akathisia-related events occurred in 25% of aripiprazole-treated patients versus 4% on placebo, making this the most likely cause of your patient's symptoms. 1
• Akathisia is frequently misinterpreted as anxiety or worsening psychiatric symptoms, leading to inappropriate medication adjustments rather than addressing the underlying extrapyramidal side effect. 4
• When aripiprazole is combined with mood stabilizers like lamotrigine, the risk of severe akathisia, increased anxiety, and even suicidal ideation increases substantially, as documented in case reports. 5

Why Quetiapine Did Not Resolve the Problem

• Quetiapine can also cause tremor and extrapyramidal symptoms, though typically less frequently than aripiprazole; switching from one antipsychotic to another without addressing the underlying akathisia mechanism often fails to resolve symptoms. 4, 6
• Quetiapine was not associated with decreased risk of relapse at any dose in a large nationwide cohort study, suggesting it may not be the optimal choice for bipolar I maintenance therapy. 6
• The persistence of shakiness after switching suggests either ongoing akathisia from quetiapine or that the original aripiprazole-induced akathisia was never properly treated before the switch. 4, 1

Immediate Management Algorithm

Step 1: Discontinue Current Antipsychotic and Treat Akathisia

• Discontinue quetiapine immediately to eliminate ongoing contribution to extrapyramidal symptoms. 4
• Initiate propranolol 20 mg twice daily, increasing to 40 mg twice daily if needed, as beta-blockers are the most effective treatment for antipsychotic-induced akathisia and essential tremor. 4, 2, 3
• Propranolol has been used to treat essential tremor for more than 40 years and is effective in approximately 50% of patients with tremor, making it the first-line pharmacologic intervention. 4, 2, 3
• Alternative beta-blockers such as metoprolol or atenolol can be substituted if propranolol causes intolerable side effects, though propranolol has the strongest evidence base. 4, 2, 3

Step 2: Address Anxiety Symptoms

• Benzodiazepines such as lorazepam 0.5–1 mg orally up to four times daily (maximum 4 mg/24 hours) can provide immediate relief of anxiety and agitation while definitive mood stabilizer therapy is initiated. 4
• In elderly or debilitated patients, reduce the lorazepam dose to 0.25–0.5 mg (maximum 2 mg/24 hours) to minimize sedation and fall risk. 4
• Benzodiazepines should be time-limited (days to weeks) to avoid tolerance and dependence, serving only as a bridge until mood stabilization is achieved. 4
• Cognitive-behavioral therapy should be initiated as the primary non-pharmacological intervention for anxiety, as combination treatment (CBT plus medication) is superior to either alone. 4

Step 3: Initiate Definitive Mood Stabilizer Therapy

• Lithium or valproate should be started as first-line mood stabilizer therapy for bipolar I disorder, as both have superior evidence for long-term efficacy compared to antipsychotic monotherapy. 7, 8, 9
• Lithium target levels should be 0.8–1.2 mEq/L for acute treatment, with baseline labs including complete blood count, thyroid function tests, urinalysis, BUN, creatinine, serum calcium, and pregnancy test in females. 7
• Valproate should be initiated at 125 mg twice daily and titrated to therapeutic blood levels of 40–90 µg/mL, with baseline liver function tests, complete blood count, and pregnancy test. 7
• Lithium reduces suicide attempts 8.6-fold and completed suicides 9-fold, an effect independent of its mood-stabilizing properties, making it particularly valuable in bipolar I disorder. 7

Alternative Antipsychotic Selection If Needed

If Antipsychotic Therapy Is Required

• If psychotic symptoms or severe mania necessitate continued antipsychotic therapy, aripiprazole and quetiapine should be avoided given this patient's documented intolerance. 1, 6
• Olanzapine 10–15 mg/day provides rapid symptomatic control for acute mania with lower akathisia risk than aripiprazole, though metabolic monitoring is essential. 10, 11
• Risperidone 2 mg/day can be effective when combined with mood stabilizers, though it carries moderate metabolic risk and prolactin elevation. 10
• Standard doses of lithium and aripiprazole were associated with the lowest risk of relapse in a large cohort study, but given this patient's aripiprazole intolerance, lithium monotherapy or lithium plus olanzapine would be preferable. 6

Monitoring and Follow-Up

Short-Term Monitoring (First 2 Weeks)

• Assess tremor severity, anxiety symptoms, and akathisia weekly using standardized scales to evaluate response to propranolol and benzodiazepine therapy. 4, 7
• Monitor for propranolol side effects including bradycardia, hypotension, and fatigue, adjusting dose as needed. 4
• Check lithium or valproate levels after 5–7 days at stable dosing to ensure therapeutic range is achieved. 7

Long-Term Maintenance (After Stabilization)

• Continue mood stabilizer therapy for at least 12–24 months after achieving stability, as premature discontinuation is associated with relapse rates exceeding 90% in noncompliant patients. 7
• Monitor lithium levels, renal function, and thyroid function every 3–6 months during maintenance therapy. 7
• For valproate, monitor serum drug levels, hepatic function, and hematological indices every 3–6 months. 7
• Gradually taper and discontinue propranolol after 2–3 months if tremor has resolved, as the underlying cause (antipsychotic-induced akathisia) will have been eliminated. 2, 3

Common Pitfalls to Avoid

Misdiagnosis and Inappropriate Treatment

• Never misinterpret akathisia as worsening anxiety or psychotic agitation, as this leads to inappropriate dose escalation of the offending antipsychotic rather than discontinuation. 4, 5
• Avoid switching from one antipsychotic to another without first treating the underlying akathisia, as multiple antipsychotics can cause similar extrapyramidal symptoms. 4, 1
• Do not use anticholinergic agents (such as benztropine) as first-line treatment for akathisia, as they are not consistently helpful; beta-blockers and benzodiazepines have superior efficacy. 4

Medication Management Errors

• Never use antipsychotic monotherapy as definitive treatment for bipolar I disorder when mood stabilizers (lithium, valproate, lamotrigine) have superior long-term efficacy and lower side-effect burden. 7, 8, 9
• Avoid combining multiple antipsychotics, as this increases metabolic and extrapyramidal side effects without improving efficacy. 10
• Do not prescribe benzodiazepines as chronic standing medications beyond the acute stabilization phase, as tolerance and dependence develop rapidly. 4

Inadequate Monitoring

• Failure to obtain baseline and ongoing laboratory monitoring for mood stabilizers can result in undetected toxicity or subtherapeutic dosing. 7
• Neglecting to assess for metabolic side effects (weight gain, glucose dysregulation, lipid abnormalities) when antipsychotics are used leads to long-term cardiovascular morbidity. 7, 8